Menu

Price Performance Heatmap

5Y Price (Market Cap Weighted)

All Stocks (4)

Company Market Cap Price
HLN Haleon plc
Respiratory Health OTC products are part of Haleon's consumer health portfolio.
$42.33B
$9.28
+1.09%
RDY Dr. Reddy's Laboratories Limited
OTC respiratory & nasal care products within consumer health segment.
$11.09B
$13.30
-1.12%
PRGO Perrigo Company plc
Respiratory & Nasal Care OTC products are part of Perrigo's consumer self-care lineup.
$2.85B
$20.73
+0.44%
AMPH Amphastar Pharmaceuticals, Inc.
BAQSIMI and Primatene MIST anchor respiratory/nasal care and OTC/inhalation product categories.
$1.20B
$25.52
+3.49%

Loading company comparison...

Loading research report...

PRGO Perrigo Company plc

Perrigo Partners with Chillhouse to Launch ‘Opill and Chill’ Collaboration

Oct 10, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Enters Exclusive Licensing Agreement for Three Proprietary Peptides

Aug 12, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Secures FDA Approval for Generic Iron Sucrose Injection (AMP-002)

Aug 11, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Reports Q2 2025 Results: BAQSIMI Sales Up 51% YoY, EPS Beats Estimates

Aug 07, 2025
AMPH Amphastar Pharmaceuticals, Inc.

JPMorgan Downgrades Amphastar Pharmaceuticals to Neutral, Lowers Price Target to $30

Jul 10, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Added to Russell Value Indices, Dropped from Dynamic Index

Jun 30, 2025
AMPH Amphastar Pharmaceuticals, Inc.

President Trump Postpones Planned EU Tariffs, Reducing Potential Economic Headwinds

May 27, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Reports Q1 2025 Results with Flat Revenues and EPS Beat

May 07, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals to Release First Quarter 2025 Earnings on May 7, 2025

Apr 30, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Subsidiary Receives FDA Drug Shortage Assistance Award for Epinephrine Injection

Mar 28, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Reports Mixed Q4 and Full Year 2024 Results, Primatene MIST Exceeds $100 Million Annual Sales

Feb 27, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals to Release Fourth Quarter and Full Year 2024 Earnings on February 27, 2025

Feb 20, 2025
AMPH Amphastar Pharmaceuticals, Inc.

Wells Fargo Initiates Coverage on Amphastar with Equal Weight Rating and $55 Price Target

Nov 23, 2024
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals Reports Q3 2024 Results with Increased Revenues and Net Income

Nov 06, 2024
AMPH Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals to Announce Third Quarter 2024 Earnings on November 6, 2024

Oct 29, 2024

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks